


**REMARKS**

Without prejudice, Applicant has herein amended claims 1, 4-9, 11, 12, 14, 20, 25, 26, 28, 31, 33, 34, 38, 43, 44 and 46, and cancelled claims 2, 3, 10, 13, 32, 54 and 55. Accordingly, the claims as amended are directed to compositions comprising pure or 5 substantially pure S,S-enantiomer of reboxetine and methods of use thereof. Applicants are unaware of any publications that suggest or teach one of ordinary skill in the art to combine S,S-reboxetine with any of the recited agents.

Claims 1, 11, 12, 14, 20, 25, 28, 31, 33-34, 38, 43 and 46 are further amended to delete the "smoking-cessation enhancing" use limitation. No new matter is introduced. Applicant respectfully requests entry of this Amendment.

The Commisioner is hereby authorized to charge any fees required under 37 C.F.R. §§1.16 and §1.17 or to credit any overpayment to Deposit Account No. 16-1445.

Respectfully submitted,

  
\_\_\_\_\_  
A. David Joran  
Registration No. 37,858  
Attorney for Applicants

Date: August 26, 2004

Pfizer, Inc.  
Patent Department  
150 East 42<sup>nd</sup> Street  
New York, NY 10017  
(212) 733-3381